All Fulcrum Publications

April 15, 2024

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

Rabi Tawil MD, Prof Kathryn R Wagner MD, Johanna I Hamel MD, Doris G Leung MD, Jeffrey M Statland MD, Prof Leo H Wang MD, Angela Genge MD, Prof Sabrina Sacconi MD, Prof Hanns Lochmüller MD, David Reyes-Leiva MD, Prof Jordi Diaz-Manera MD, Jorge Alonso-Perez MD, Nuria Muelas PhD, Juan J Vilchez MD, Alan Pestronk MD, Summer Gibson MD, Prof Namita A Goyal MD, Prof Lawrence J Hayward MD, Nicholas Johnson MD, Samantha LoRusso MD, John G Jiang PhD

March 3, 2024

Facioscapulohumeral Muscular Dystrophy (FSHD) Disease Progression and Losmapimod Efficacy Assessed by Reachable Workspace in Both Arms

Rabi Tawil, MD, University of Rochester Medical Center, Joost Kools, MD, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Marie-Helene Jouvin, MD, Fulcrum Therapeutics, John Jiang, PhD, Fulcrum Therapeutics

March 3, 2024

Losmapimod, a p38 Small Molecule Inhibitor, Selectively Inhibits the DUX4 Program Without Negatively Impacting Myogenesis in FSHD

Genevieve Wilson, Erin Valentine, Joseph Maglio, Anthony Accorsi, Alejandro Rojas and Jeff Jacobs

March 1, 2024

Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation

Megan M McNiff, Sheila Hawkins, Bine Haase, Joanne Bullivant, Tammy McIver, Olga Mitelman, Nicholas Emery, Giorgio Tasca, Nicol Voermans, Jordi Diaz-Manera

December 11, 2023

Single-cell transcriptome analyses further elucidate the mechanism of action of EED inhibition on HbF induction

Summer Xia Han, Emily Fitz, Allysa Allen, Avik Choudhuri, Caroline V. Sartain, Paul A. Bruno, Jeffrey W. Jacobs, Billy Stuart

October 3, 2023

Safety and Tolerability Data with Losmapimod in FSHD

M-H Jouvin, V Ramana, J Jiang

October 3, 2023

A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

L Barnieh, R Beckerman, H Emich, K Eichinger, A Eldar-Lissai

June 15, 2023

Development of the HealthMeasures Facioscapulohumeral Muscular Dystrophy-32 (HM FSHD-32) Patient-Reported Outcome Measure

Shaunfield S, K Kaiser, CN Hurt, GJ Greene, D Peipert, A Eldar-Lissai, D Cella